A novel method for the analysis of drug-resistant phenotypes of hepatitis B virus

International Journal of Molecular Medicine

Volumn 31, Issue 4, 2013, Pages 975-981

  Qin, Bo ^a,b   He, Tingting ^a   Chen, Zhijun ^a   Xu, Wenying ^a   Pan, Guoshao ^a   Tu, Chunyu ^a  

^a Shaoxing Center for Disease Control and Prevention   (China)

^b WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

Co transfection; Drug resistant phenotype analysis; Hepatitis B virus; Nucleos(t)ide analogues; Quasispecies

Indexed keywords

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DNA TEMPLATE; HEPATITIS B; LIVER CELL CARCINOMA; NONHUMAN; NONSENSE MUTATION; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRION; VIRUS REPLICATION;

ANTI-HIV AGENTS; BLOTTING, SOUTHERN; CELL LINE, TUMOR; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; PHENOTYPE; PLASMIDS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSFECTION; VIRUS REPLICATION;

EID: 84875233850     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1277     Document Type: Article

References (28)

1. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97-107, 2004.
2. Lee WM: Hepatitis B virus infection. N Engl J Med 337: 1733-1745, 1997.
3. Huang LR, Wu HL, Chen PJ and Chen DS: An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA 103: 17862-17867, 2006.
4. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C and Tacke F: The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 49: 1158-1165, 2009.
5. Zoulim F and Locarnini S: Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137: 1593-1608, 2009.
6. von Kleist M, Metzner P, Marquet R and Schutte C: HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection. PLoS Comput Biol 8: e1002359, 2012.
7. Galmarini CM, Mackey JR and Dumontet C: Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia15: 875-890, 2001.
8. Sabini E, Hazra S, Konrad M and Lavie A: Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides. J Med Chem 50: 3004-3014, 2007.
9. Liu F, Chen L, Yu DM, et al: Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. Gut 60: 1269-1277, 2011.
10. Nishijima N, Marusawa H, Ueda Y, et al: Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. PloS One 7: e35052, 2012.
11. Brunelle MN, Jacquard AC, Pichoud C, et al: Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41: 1391-1398, 2005.
12. Levine S, Hernandez D, Yamanaka G, et al: Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 46: 2525-2532, 2002.
13. Pallier C, Castera L, Soulier A, et al: Dynamics of hepatitis B virus resistance to lamivudine. J Virol 80: 643-653, 2006.
14. Tenney DJ, Levine SM, Rose RE, et al: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 48: 3498-3507, 2004.
15. Tenney DJ, Rose RE, Baldick CJ, et al: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49: 1503-1514, 2009.
16. Walsh AW, Langley DR, Colonno RJ and Tenney DJ: Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. PloS One 5: e9195, 2010.
17. Liu Y, Wang CM, Cheng J, et al: Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility. Chin Med J 122: 1585-1586, 2009.
18. Yuen MF and Lai CL: Treatment of chronic hepatitis B. Lancet Infect Dis 1: 232-241, 2001.
19. Lee YS, Suh DJ, Lim YS, et al: Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43: 1385-1391, 2006.
20. Jeon JW, Shin HP, Lee JI, et al: Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. Dig Dis Sci 57: 1358-1365, 2012.
21. Svicher V, Cento V, Salpini R, et al: Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development. Dig Liver Dis 43: 975-983, 2011.
22. Lei YC, Hao YH, Zhang ZM, et al: Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo. World J Gastroenterol 12: 4492-4497, 2006.
23. Wu C, Deng W, Deng L, et al: Amino acid substitutions at positions 122 and 145 of hepatitis B virus surface antigen (HBsAg) determine the antigenicity and immunogenicity of HBsAg and influence in vivo HBsAg clearance. J Virol 86: 4658-4669, 2012.
24. Qin B, Budeus B, Cao L, et al: The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir. Antiviral Research 97: 93-100, 2013.
25. Qiu J, Qin B, Rayner S, et al: Novel evidence suggests Hepatitis B virus surface proteins participate in regulation of HBV genome replication. Virol Sin 26: 131-138, 2011.
26. Kain SR: Use of secreted alkaline phosphatase as a reporter of gene expression in mammalian cells. Methods Mol Biol 63: 49-60, 1997.
27. Blum HE, Galun E, Liang TJ, et al: Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication. J Virol 65: 1836-1842, 1991.
28. Heipertz RA Jr, Starkey JL, Miller TG, etal: trans-Complementation of HBV rtM204I mutant replication by HBV wild-type polymerase. Virology 388: 57-67, 2009.